Impressions of the symposium in Lübeck

Prof. Dr. Gabriela Riemekasten hosted the 5th International Symposium on Regulatory Autoantibodies in Lübeck. Many guests, including international guests, accepted the invitation to the Hanseatic city. Once again this year, numerous interesting presentations were given on the topic of GPCRs and their causal relationship in patients was discussed. The methods for eliminating pathogenic autoantibodies and…

Details

5th International Symposium on Regulatory Autoantibodies on September 26-27th, 2024

Save the date! On September 26-27th, 2024, the 5th International Symposium on Regulatory Autoantibodies will take place in Lübeck! Under the direction of Prof. Dr. med. Gabriela Riemekasten, excellent speakers such as Prof. Dr. Carmen Scheibenbogen, Prof. Yehuda Shoenfeld and others will focus on the connection of RABs to the pathogenesis of diseases and their…

Details

lab closed for holiday

Please note that our laboratory will be closed for an extended weekend due to the public holiday on 09.05.2024! Please only send samples that reach our laboratory by Wednesday, 08.05.24. Samples will not be accepted at the weekend. From 13.05.24 we will be there for you again as usual.

Details

CellTrend receives new patent

In 2018, James P. Allison and Tasuku Honjo received the Nobel Prize in Medicine for the discovery of a tumor therapy through negative immune regulation. Here, the binding between PD1 (Programmed cell death protein 1) and PD-L1 (Programmed cell death protein 1 ligand) is inhibited. CellTrend has discovered autoantibodies against PD1 and PD-L1 in tumor…

Details

New study about severity of Long-COVID symptoms and their correlation with the increased level of autoantibodies was published

A new study about severity of neurological Long-COVID symptoms and their correlation with the increased level of autoantibodies was published. In Table 1 you can have a look at the 200 individuals which were recruited and put into 3 groups. One group with 72 patients were diagnosed with Long-COVID, second group with 58 patients had…

Details